An Alzheimer’s expert digs into the data from the Biogen trial

Puzzled by those controversial Alzheimer’s disease data from Biogen and Eisai? We asked an expert to break down what they mean for patients, for science, and for the future of what could be a promising treatment for a devastating disease.

Dr. Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation, joined us to answer STAT Plus subscribers’ questions on BAN2401, the therapy from Biogen and Eisai that just completed Phase 2 testing.

Here are highlights from the call — and Fillet’s takeaways. His responses have been lightly edited for clarity.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In